Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
CRM
IHD
ACZ885-IL-1 beta inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
Read-out Milesstone(s)
Publication
NCT03631199 CANOPY-1 (CACZ885U2301)
1st Line Non-small cell lung cancer (NSCLC)
Phase 3
627
Safety run-in part: Incidence of dose limiting toxicities
Double-blind, randomized, placebo-controlled part: Progression free survival (PFS)
Overall survival (OS)
Canakinumab or matching placebo in combination with pembrolizumab and
platinum-based doublet chemotherapy
Patients with
Histologically confirmed Stage IIIB, IV NSCLC with no prior systemic anticancer
therapy
Squamous and non-squamous NSCLC
No EGFR mutation and ALK rearrangement
H2-2021
Johnson B et al. Presented at AACR-NCI-EORTC 2019 (safety run-in)
Planned abstract submission to congress in 2H 2021
98 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation